Abstract Number: 2301 • ACR Convergence 2023
Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years
Background/Purpose: SLE patients often experience relapse in the course of treatment, in spite of the progress of therapeutic strategy in SLE. The purpose of this…Abstract Number: 0124 • ACR Convergence 2023
Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network
Background/Purpose: Patients with SLE experience increased all-cause mortality and have a higher risk of hospitalization than the general population. Recently the classification criteria for SLE…Abstract Number: 0656 • ACR Convergence 2023
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
Background/Purpose: Interstitial Lung Disease (ILD) in systemic sclerosis (SSc) is a common complication that has varied progression rate and prognosis. Different progression definitions include minimal…Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…Abstract Number: 2309 • ACR Convergence 2023
Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…Abstract Number: 0127 • ACR Convergence 2023
Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study
Background/Purpose: Cardiopulmonary complications are the number one cause of mortality in Systemic sclerosis (SSc). We studied the prevalence, cumulative incidence, predictors and impact of interstitial…Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…Abstract Number: 1468 • ACR Convergence 2023
Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have higher risks of developing cardiovascular disease (CVD). Traditional risk factors do not adequately capture the risk of…Abstract Number: 2319 • ACR Convergence 2023
Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences. We need to…Abstract Number: 0222 • ACR Convergence 2023
Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab
Background/Purpose: Rituximab (RTX) is widely used in immune mediated inflammatory disease (IMID) patients refractory to conventional treatment. Previous studies have indicated that RTX in IMID…Abstract Number: 0790 • ACR Convergence 2023
Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)
Background/Purpose: SSc-ILD is the leading cause of death in SSc affecting around 50% of the patients. Lung tissue of patients with early-stage SSc-ILD is characterized…Abstract Number: 1483 • ACR Convergence 2023
High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study
Background/Purpose: Lupus nephritis (LN) is a major manifestation which develops in more than 50% of patients with systemic lupus erythematosus (SLE), and is also a…Abstract Number: 2482 • ACR Convergence 2023
Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis
Background/Purpose: This study aimed to determine predictors of treatment response and radiographic progression following the initiation of biological disease-modifying antirheumatic medications (bDMARDs) in patients with…Abstract Number: 0253 • ACR Convergence 2023
Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity
Background/Purpose: Anti-ribonucleoprotein (RNP) and anti-Sm/RNP common motif antibodies play a critical role in diagnosing patients with systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD)…Abstract Number: 1120 • ACR Convergence 2023
Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients
Background/Purpose: Despite rheumatology guidelines' emphasis on treat-to-target-serum-urate (SU) levels (<6 or <5 mg/dL, urate crystal sub-saturation points), this pathophysiology-based recommendation is not accepted in primary…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 21
- Next Page »